Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Imine. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN111170886B details a novel mild oxidation and demethylation route for dezocine impurities, ensuring high purity and scalable pharmaceutical intermediate manufacturing.
Patent CN102125875A details a novel ferrocenyl-palladium catalyst for one-pot biaryl synthesis, offering high yields and streamlined manufacturing for pharmaceutical intermediates.
Patent CN108097323B discloses a green room-temperature synthesis of imines using ligand-modified gold catalysts, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturers.
High-purity chiral amine intermediate for levopraziquantel. Enzymatic process ensures cost reduction and supply reliability for pharmaceutical manufacturing.
Patent CN110128357B reveals a mild Cs2CO3-catalyzed route for pyrazine derivatives, offering high purity and scalable manufacturing for pharmaceutical intermediates.
Patent CN107384885B reveals enzymatic synthesis of chiral amines. Achieve cost reduction in API manufacturing with high conversion and optical purity.
Discover a novel room-temperature aerobic oxidation method for imine synthesis using Cu/TEMPO. Ideal for cost-effective pharmaceutical intermediate manufacturing and supply chain stability.
Patent CN101108860A reveals a novel synthesis for beta-enolimine boron difluoride complexes, offering high yields and visible light fluorescence for advanced photoluminescent applications.
Novel electrochemical method for alkenylsulfinyl imine synthesis reduces cost and steps significantly. Reliable supply chain partner for high purity pharmaceutical intermediates manufacturing and global distribution.
Novel oxidation-demethylation route for dezocine impurity 3 ensures high purity and scalable production for global API manufacturers.
Patent CN104693144A reveals a safer synthetic route for pharmaceutical intermediates. Achieve high purity and cost reduction in pharmaceutical intermediates manufacturing with scalable processes.
Patent CN115948360A details an imine reductase mutant achieving >99.5% conversion and 99.6% ee for nicotine analog intermediates, offering significant cost and supply chain advantages.
Patent CN102627590A details a mild route to chiral alpha-tribromomethyl amines. Offers high optical purity and scalable conditions for API intermediates.
Patent CN117229187A reveals a room-temperature synthesis method for thioimine esters. This breakthrough offers significant cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN117887739A reveals enzymatic route for moxifloxacin intermediate offering cost reduction and high purity for pharmaceutical manufacturing supply chains.
Patent CN101580488B details TiCl4-catalyzed ligand synthesis yielding >80%. Enables high-selectivity linear alpha-olefin production with reduced costs.
Patent CN115260177B details a novel four-step synthesis for high-energy density materials. This report analyzes cost reduction and supply chain reliability for industrial scale-up.
High-yield imine reductase method for ephedrine production offers supply chain stability and cost efficiency for pharmaceutical intermediates.
Patent CN114736882B reveals high-efficiency biocatalysis for antiviral intermediates. Offers supply chain stability and cost reduction in API manufacturing without heavy metals.
Patent CN111057729B reveals enzymatic synthesis for high-purity Larotrectinib intermediates. Discover cost-effective, scalable biocatalytic manufacturing solutions.